ArticleJournal of thoracic disease2025
The value of fibrosis score and
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Compared to general population, patients with interstitial lung disease (ILD) shows an increased risk of lung cancer (LC), and higher LC complications. Hence, this study aims to analyze the factors related to the postoperative complications and mortality of patients with malignant lung tumor-and ILD after surgical resection. Methods: This study analyzed the clinical information, surgical conditions, preoperative computed tomography (CT) and positron emission tomography (PET) examination data, as well as postoperative follow-up data of 60 non-small cell LC patients and 60 non-small cell LC patients with interstitial lung disease (LC-ILD). In this study, 120 patients with non-small cell LC were retrospectively reviewed, of which 60 were assigned to LC group and 60 to LC-ILD group. Cohorts were evaluated for differences in clinical data, surgical conditions, preoperative CT/PET examination data, and postoperative follow-up data. Results: The postoperative complications in the LC-ILD group were slightly higher than those in the LC group (P<0.001), and the prognosis of LC patients with ILD was significantly worse than that of those without ILD (P=0.048). The standardized uptake value ratio (SUVR) of noncancerous interstitial pneumonia (IP) area in patients with postoperative complications was higher than that of patients without complications (P=0.005), and it was the risk factor for postoperative complications in LC-ILD group [hazard ratio (HR) 3.384 (1.023-25.441); P=0.02]. Until the end of follow-up, the CT scores of non-survivors were higher than those of survivors (9.30±3.56 Conclusions: The postoperative complications and mortality of LC-ILD significantly increase. Higher SUVR of noncancerous IP area usually indicates an increase of postoperative complications. Higher CT score and smoking history suggest a poor prognosis. A follow-up longitudinal study is needed to validate the findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.